> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Iradimed Lowers The Top Of Its 2026 Revenue Range To $93.1 Million After A Record Quarter
- URL: https://www.bullished.co/iradimed-lowers-the-top-of-its-2026-revenue-range-to-93-1-million-after-a-record-quarter-47754c0d/
- Published: 2026-10-30T20:22:47.000Z
- Updated: 2026-10-30T20:22:47.000Z
- Description: Third-quarter sales rose 14% to $24.2 million, but gross margin slipped to 76% and inventory grew.
- Author: Matteo Parrino
- Tags: Earnings, IRMD, Industry: Healthcare

[Iradimed](https://www.bullished.co/tag/irmd/), which makes MRI-compatible IV pumps and patient monitors, cut the ceiling on its full-year revenue outlook to [$93.1 million](https://www.sec.gov/Archives/edgar/data/0001325618/000162828026068454/irmd-2026930xexx991.htm?ref=bullished.co) from $96.0 million, even as it posted record third-quarter sales of $24.2 million, the company said Friday. The [10-Q](https://www.sec.gov/Archives/edgar/data/0001325618/000162828026068576/irmd-20260930.htm?ref=bullished.co) filed the same day shows gross margin down from a year earlier.

## A narrower, lower guidance range

Full-year revenue is now guided to [$91.6 million](https://www.marketwatch.com/story/iradimed-shares-fall-on-lower-full-year-revenue-earnings-guidance-cb4c862a?ref=bullished.co) to $93.1 million, against $91.0 million to $96.0 million before. Earnings per share on a standard accounting basis is guided to $1.90 to $1.94, replacing $1.90 to $2.05.

For the fourth quarter, the company expects revenue of [$25.0 million](https://www.marketwatch.com/story/iradimed-shares-fall-on-lower-full-year-revenue-earnings-guidance-cb4c862a?ref=bullished.co) to $26.5 million and earnings of $0.53 to $0.57 per share. CEO Roger Susi said the quarter would reach a $100.0 million revenue run rate and that record bookings leave the company "well positioned for a strong finish to the year."

## Record sales, thinner margin

Third-quarter revenue rose 14% from $21.2 million. Net income reached [$6.5 million](https://finance.yahoo.com/markets/stocks/articles/iradimed-q3-earnings-snapshot-123930803.html?ref=bullished.co), or $0.51 per diluted share, against $5.6 million, or $0.43, a year earlier.

Gross margin fell to 76% from 78%, which the 10-Q attributes to initial production inefficiencies on new product manufacturing. Cost of revenue climbed 22% to $5.7 million, outpacing sales growth.

The filing credits the quarter's revenue increase primarily to changes in the sales incentive plan for monitors, infusion pumps and disposables. Pump revenue was $8.7 million, against $8.3 million a year earlier, while monitor revenue rose to $8.0 million from $6.9 million. International sales jumped 45% to $4.5 million.

## Inventory builds as cash flow improves

Inventory stood at $13.5 million at September 30, up from $11.6 million at the end of 2025, with raw materials at $11.7 million versus $9.6 million. The company said increased inventory purchases partly offset operating cash flow.

Free cash flow for the first nine months was $20.1 million, against $11.0 million a year earlier, when the company was still spending on its new corporate office and manufacturing facility. Cash totaled $63.3 million.

The company, which sells mainly to hospitals through 28 field sales representatives in the US and independent distributors abroad, declared a $0.20 quarterly dividend payable November 27 to holders of record on November 13.

Fourth-quarter revenue of $25.0 million to $26.5 million is the figure the new full-year range now depends on.

### Sources

- [10-Q Filing — Iradimed (IRMD)](https://www.sec.gov/Archives/edgar/data/0001325618/000162828026068576/irmd-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Iradimed (IRMD), Q2 FY2026 filed 2026-07-31 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001325618/000162828026051402/irmd-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, irmd-2026930xexx991.htm) — Iradimed, filed 2026-10-30](https://www.sec.gov/Archives/edgar/data/0001325618/000162828026068454/irmd-2026930xexx991.htm?ref=bullished.co) — SEC EDGAR
- [Iradimed Shares Fall on Lower Full-Year Revenue, Earnings Guidance](https://www.marketwatch.com/story/iradimed-shares-fall-on-lower-full-year-revenue-earnings-guidance-cb4c862a?ref=bullished.co) — MarketWatch
- [IRadimed: Q3 Earnings Snapshot](https://finance.yahoo.com/markets/stocks/articles/iradimed-q3-earnings-snapshot-123930803.html?ref=bullished.co) — Associated Press
- [iRadimed Q3 2026 Earnings Call Transcript](https://www.benzinga.com/news/26/10/62747150/iradimed-q3-2026-earnings-call-transcript?ref=bullished.co) — benzinga.com
- [Iradimed anticipates $25M-$26.5M Q4 revenue as 3870 pump output targets 50%+ sequential growth (NASDAQ:IRMD) | Seeking Alpha](https://seekingalpha.com/news/4661607-iradimed-anticipates-25m-26%5F5m-q4-revenue-as-3870-pump-output-targets-50-percent-sequential?ref=bullished.co) — seekingalpha.com
- [IRadimed: Q3 Earnings Snapshot – WTOP News](https://wtop.com/national/2026/10/iradimed-q3-earnings-snapshot/?ref=bullished.co) — wtop.com

### More on Iradimed

- [Iradimed Raises Low End Of Profit Outlook, Cuts Top Of Revenue Range, As Q3 Sales Hit $24.2 Million](https://www.bullished.co/iradimed-raises-low-end-of-profit-outlook-cuts-top-of-revenue-range-as-q3-sales-hit-24-2-b40956d1/)

[All Iradimed (IRMD) coverage →](https://www.bullished.co/tag/irmd/)